COMBINE 1: A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
Study Details
Study Description
Brief Summary
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin icodec taken once a week in people with type 2 diabetes.
The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to insulin icodec.
Participants will either get IcoSema or insulin icodec. Which treatment participants get is decided by chance. IcoSema and insulin icodec are both new medicines that doctors cannot prescribe.
Participants will get IcoSema or insulin icodec, which participants must inject once a week with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach.
The study will last for about 1 year and 1 month. Participants will have 21 clinic visits, 31 phone/video calls with the study doctor, and 4 contacts with the site that can either be clinic visits or phone/video calls At 11 clinic visits participants will have blood samples taken. At 7 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit.
Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.
Not applicable for China: Participants will be asked to wear a sensor that measures their blood sugar level all the time during a 5 week period at the end of the study.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: IcoSema
|
Drug: IcoSema
Participants will receive once weekly IcoSema subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
|
| Active Comparator: Insulin icodec
|
Drug: Insulin icodec
Participants will receive once weekly Insulin icodec subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
|
Outcome Measures
Primary Outcome Measures
- Change in glycated haemoglobin (HbA1c) [From baseline week 0 (V2) to week 52 (V54)]
% point
Secondary Outcome Measures
- Change in body weight [From baseline week 0 (V2) to week 52 (V54)]
Kg
- Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) [From baseline week 0 (V2) to week 57 (V56)]
Number of episodes
Eligibility Criteria
Criteria
Key inclusion criteria
-
Male or female and age above or equal to 18 years at the time of signing informed consent.
-
Diagnosed with type 2 diabetes mellitus 180 days or more before screening.
-
HbA1c of 7.0 10.0% (53.0 85.8 mmol/mol) (both inclusive) as assessed by central laboratory on the day of screening.
-
Treated with once daily or twice daily basal insulin (neutral protamine hagedorn insulin, insulin degludec, insulin detemir, insulin glargine 100 units/mL, or insulin glargine 300 units/mL) 20- 80 units/day for 90 days or more before screening. Short term bolus insulin treatment for a maximum of 14 days before screening is allowed, as is prior insulin treatment for gestational diabetes. The treatment can be with or without any of the following anti diabetic drugs with stable doses for 90 days or more before screening:
-
Metformin
-
Sulfonylureas (a)
-
Meglitinides (glinides) (a)
-
DPP 4 inhibitors (a)
-
Sodium glucose co transporter 2 inhibitors
-
Alpha glucosidase inhibitors
-
Thiazolidinediones
-
Marketed oral combination products only including the products listed above.
- Body mass index (BMI) below or equal to 40.0 kg/m^2. (a) Sulfonylureas, meglitinides (glinides) and DPP 4 inhibitors must be discontinued at randomisation.
Key exclusion criteria
-
Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method.
-
Anticipated initiation or change in concomitant medication (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or systemic corticosteroids).
-
Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening.
-
Any episodes (as declared by the participant or in the medical records.) of diabetic ketoacidosis within 90 days before screening.
-
Presence or history of pancreatitis (acute or chronic) within 180 days before screening.
-
Any of the following: Myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within 180 days before screening.
-
Chronic heart failure classified as being in New York Heart Association Class IV at screening.
-
Recurrent severe hypoglycaemic episodes within the last year (12 months) as judged by the investigator.
-
Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days before screening or in the period between screening and randomisation. Pharmacological pupil dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Novo Nordisk Investigational Site | Roswell | Georgia | United States | 30076 |
| 2 | Novo Nordisk Investigational Site | Greensboro | North Carolina | United States | 27408 |
| 3 | Novo Nordisk Investigational Site | San Antonio | Texas | United States | 78224 |
| 4 | Novo Nordisk Investigational Site | Herston | Queensland | Australia | 4029 |
| 5 | Novo Nordisk Investigational Site | Beijing | Beijing | China | 100044 |
| 6 | Novo Nordisk Investigational Site | Huizhou | Guangdong | China | 516001 |
| 7 | Novo Nordisk Investigational Site | Changzhou | Jiangsu | China | 213003 |
| 8 | Novo Nordisk Investigational Site | Nanjing | Jiangsu | China | 210011 |
| 9 | Novo Nordisk Investigational Site | Zhenjiang | Jiangsu | China | 212001 |
| 10 | Novo Nordisk Investigational Site | Shanghai | Shanghai | China | 200240 |
| 11 | Novo Nordisk Investigational Site | Tianjin | Tianjin | China | 300052 |
| 12 | Novo Nordisk Investigational Site | Kuopio | Finland | 70100 | |
| 13 | Novo Nordisk Investigational Site | Raisio | Finland | 21200 | |
| 14 | Novo Nordisk Investigational Site | Turku | Finland | 20520 | |
| 15 | Novo Nordisk Investigational Site | Ähtäri | Finland | 63700 | |
| 16 | Novo Nordisk Investigational Site | Mexico City | México, D.F. | Mexico | 03300 |
| 17 | Novo Nordisk Investigational Site | Monterrey | Nuevo León | Mexico | 64460 |
| 18 | Novo Nordisk Investigational Site | Aguascalientes | Mexico | 20230 |
Sponsors and Collaborators
- Novo Nordisk A/S
Investigators
- Study Director: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NN1535-4591
- U1111 1260 8259
- 2020 005281 34